Relmada Therapeutics, Inc. RLMD
Set alert
3.58 USD +0.14 +4.07%
At close · Oct 30
3.50 -0.08 -2.23%
After hours · Oct 30, 4:13 PM ET
3.31 Day range 3.66
2.20 52-week range 7.86
- YTD
- -25.88%
- 1 year
- +54.31%
- Open
- 3.42
- Prev close
- 3.44
- Mkt cap
- 381.88M
- Vol
- 1.41M
- Avg vol
- 1.33M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.31
- High
- 3.66
- Forward P/E
- -0.19
- Beta
- 0.41
- Short ratio
- 4.52
- Inst. own
- 46.06%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.53
- 200-d avg
- 3.33
- 1y target
- 0.86667
5D chart
Signals (63)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 10:55 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:25 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:15 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:45 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 29, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| RSI: Overbought | Oct 28, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 4 days ago |
| RSI: Oversold | Oct 27, 2:20 PM | 4 days ago |
| RSI: Oversold | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
Key statistics
- Market cap
- 11.45M
- Enterprise value
- 27.93M
- Trailing P/E
- 0.00
- Forward P/E
- -0.19
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.13
- EPS (TTM)
- -2.86
- Beta
- 0.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -18.51M
- Total cash
- 70.44M
- Total debt
- 0
- Return on equity
- -100.41%
- Shares outstanding
- 30.17M
- Short % of float
- 4.23%
- 50-day average
- 2.53
- 200-day average
- 3.33
Analyst view
Consensus: none
Price target (mean) 0.86667 -75.8% downside
Now 3.58
- Target (low)
- 0.60
- Target (mean)
- 0.86667
- Target (high)
- 1.00
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RLMD Revenue — quarterly 0
RLMD Net income — quarterly -12.91M
RLMD EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.65 | -0.72 | -0.07 | -10.77% |
| Aug 7, 2024 | Jun 1, 2024 | -0.83 | -0.59 | +0.24 | +28.92% |
| May 8, 2024 | Mar 1, 2024 | -0.90 | -0.72 | +0.18 | +20.00% |
| Mar 19, 2024 | Dec 1, 2023 | -0.88 | -0.84 | +0.04 | +4.55% |
| Nov 8, 2023 | Sep 1, 2023 | -0.95 | -0.73 | +0.22 | +23.16% |
| Aug 8, 2023 | Jun 1, 2023 | -0.92 | -0.84 | +0.08 | +8.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Mizuho | down | Outperform | Neutral |
| Dec 4, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Jun 5, 2024 | Goldman Sachs | down | Neutral | Sell |
| Jun 15, 2023 | Mizuho | reit | Buy | Buy |
| Jan 23, 2023 | SVB Leerink | main | — | Outperform |
| Oct 14, 2022 | Goldman Sachs | down | Buy | Neutral |
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- relmada.com
News
- Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call
- Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
- Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
- 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
- After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
- Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Your note
Sign in to keep a note on RLMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASAMENTO CHARLES J | Director | Stock Gift | Oct 21, 2024 | 0 |
| ENCE CHARLES | Officer | Purchase | Jan 30, 2024 | 38,970 |
| KELLY PAUL EDWARD | Director | Purchase | Sep 8, 2024 | 212,295 |
| O'GORMAN CEDRIC | Officer | Purchase | May 22, 2023 | 10,121 |
| SHENOUDA MAGED R | Chief Financial Officer | Purchase | Sep 10, 2024 | 88,335 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | Sep 10, 2024 | 384,024 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Resources, Inc. | 13.16% | 1,302,151 | 494.30K | Sep 29, 2024 |
| Vanguard Group Inc | 12.70% | 1,256,705 | 477.05K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 11.99% | 1,186,452 | 450.38K | Sep 29, 2024 |
| Parsons Capital Management, Inc. | 10.13% | 1,002,695 | 380.62K | Sep 29, 2024 |
| Palo Alto Investors Lp | 7.40% | 732,400 | 278.02K | Sep 29, 2024 |
| Deep Track Capital, Lp | 6.82% | 674,833 | 256.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8.61% | 851,916 | 323.39K | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 3.78% | 374,029 | 141.98K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 3.57% | 353,625 | 134.24K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 1.59% | 157,021 | 59.60K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 1.01% | 100,177 | 38.03K | Sep 29, 2024 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.94% | 93,077 | 35.33K | Oct 30, 2024 |